Clinical Trial

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Study acronym: ETNA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Protocol Amendment History 6 changes
notable Trial sites expanded: 17 -> 24 locations 2026-07-22
notable Trial sites expanded: 11 -> 17 locations 2026-06-30
notable Trial sites expanded: 6 -> 9 locations 2026-05-19
notable Trial sites expanded: 3 -> 6 locations 2026-05-05
critical Recruitment opened 2026-04-22
notable Trial sites expanded: 0 -> 3 locations 2026-04-22
Trial Details
NCT Number NCT07501702
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Myasthenia Gravis, Generalized
Enrollment 30 participants
Start Date 2026-05-13
Primary Completion 2029-03-02 (estimated)
Study Completion 2029-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-03